Seek Returns logo

EHC vs. RGC: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at EHC and RGC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolEHCRGC
Company NameEncompass Health CorporationRegencell Bioscience Holdings Limited
CountryUnited StatesHong Kong
GICS SectorHealth CareHealth Care
GICS IndustryHealth Care Providers & ServicesPharmaceuticals
Market Capitalization12.76 billion USD7.83 billion USD
ExchangeNYSENasdaqCM
Listing DateSeptember 24, 1986July 16, 2021
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of EHC and RGC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

EHC vs. RGC: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolEHCRGC
5-Day Price Return0.95%5.97%
13-Week Price Return3.58%-9.33%
26-Week Price Return26.56%1,414.71%
52-Week Price Return32.30%10,200.00%
Month-to-Date Return4.32%9.96%
Year-to-Date Return37.54%11,784.62%
10-Day Avg. Volume0.60M0.19M
3-Month Avg. Volume0.78M1.06M
3-Month Volatility26.74%266.49%
Beta0.952.25

Profitability

Return on Equity (TTM)

EHC

24.70%

Health Care Providers & Services Industry

Max
24.86%
Q3
15.79%
Median
8.56%
Q1
5.75%
Min
-1.64%

In the upper quartile for the Health Care Providers & Services industry, EHC’s Return on Equity of 24.70% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

RGC

-54.75%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.85%
Q1
5.40%
Min
-10.91%

RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

EHC vs. RGC: A comparison of their Return on Equity (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

EHC

9.22%

Health Care Providers & Services Industry

Max
11.56%
Q3
5.45%
Median
2.83%
Q1
1.13%
Min
-1.71%

A Net Profit Margin of 9.22% places EHC in the upper quartile for the Health Care Providers & Services industry, signifying strong profitability and more effective cost management than most of its peers.

RGC

--

Pharmaceuticals Industry

Max
40.67%
Q3
19.07%
Median
12.31%
Q1
4.50%
Min
-9.91%

Net Profit Margin data for RGC is currently unavailable.

EHC vs. RGC: A comparison of their Net Profit Margin (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

EHC

17.06%

Health Care Providers & Services Industry

Max
19.08%
Q3
9.66%
Median
4.77%
Q1
2.46%
Min
-0.83%

An Operating Profit Margin of 17.06% places EHC in the upper quartile for the Health Care Providers & Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

RGC

--

Pharmaceuticals Industry

Max
45.78%
Q3
23.14%
Median
16.68%
Q1
7.98%
Min
-7.13%

Operating Profit Margin data for RGC is currently unavailable.

EHC vs. RGC: A comparison of their Operating Profit Margin (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Profitability at a Glance

SymbolEHCRGC
Return on Equity (TTM)24.70%-54.75%
Return on Assets (TTM)7.91%-51.38%
Net Profit Margin (TTM)9.22%--
Operating Profit Margin (TTM)17.06%--
Gross Profit Margin (TTM)95.62%--

Financial Strength

Current Ratio (MRQ)

EHC

1.06

Health Care Providers & Services Industry

Max
2.00
Q3
1.51
Median
1.29
Q1
0.92
Min
0.14

EHC’s Current Ratio of 1.06 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.

RGC

42.68

Pharmaceuticals Industry

Max
4.65
Q3
2.64
Median
1.85
Q1
1.26
Min
0.78

RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

EHC vs. RGC: A comparison of their Current Ratio (MRQ) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

EHC

1.08

Health Care Providers & Services Industry

Max
2.29
Q3
1.24
Median
0.74
Q1
0.50
Min
0.00

EHC’s Debt-to-Equity Ratio of 1.08 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

RGC

0.00

Pharmaceuticals Industry

Max
1.75
Q3
0.82
Median
0.35
Q1
0.13
Min
0.00

Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

EHC vs. RGC: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

EHC

6.58

Health Care Providers & Services Industry

Max
14.47
Q3
7.50
Median
4.52
Q1
2.12
Min
-4.44

EHC’s Interest Coverage Ratio of 6.58 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.

RGC

--

Pharmaceuticals Industry

Max
103.95
Q3
43.60
Median
9.83
Q1
2.37
Min
-42.71

Interest Coverage Ratio data for RGC is currently unavailable.

EHC vs. RGC: A comparison of their Interest Coverage Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

SymbolEHCRGC
Current Ratio (MRQ)1.0642.68
Quick Ratio (MRQ)0.8741.89
Debt-to-Equity Ratio (MRQ)1.080.00
Interest Coverage Ratio (TTM)6.58--

Growth

Revenue Growth

EHC vs. RGC: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

EHC vs. RGC: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

EHC

0.53%

Health Care Providers & Services Industry

Max
5.93%
Q3
2.59%
Median
1.35%
Q1
0.00%
Min
0.00%

EHC’s Dividend Yield of 0.53% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.

RGC

0.00%

Pharmaceuticals Industry

Max
7.14%
Q3
3.45%
Median
2.17%
Q1
0.33%
Min
0.00%

RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

EHC vs. RGC: A comparison of their Dividend Yield (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

EHC

12.84%

Health Care Providers & Services Industry

Max
185.33%
Q3
74.82%
Median
36.00%
Q1
0.00%
Min
0.00%

EHC’s Dividend Payout Ratio of 12.84% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

RGC

0.00%

Pharmaceuticals Industry

Max
199.58%
Q3
97.17%
Median
53.47%
Q1
22.97%
Min
0.00%

RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

EHC vs. RGC: A comparison of their Dividend Payout Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Dividend at a Glance

SymbolEHCRGC
Dividend Yield (TTM)0.53%0.00%
Dividend Payout Ratio (TTM)12.84%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

EHC

24.03

Health Care Providers & Services Industry

Max
40.02
Q3
29.75
Median
21.09
Q1
14.18
Min
7.05

EHC’s P/E Ratio of 24.03 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

RGC

--

Pharmaceuticals Industry

Max
45.19
Q3
27.91
Median
20.59
Q1
15.08
Min
3.79

P/E Ratio data for RGC is currently unavailable.

EHC vs. RGC: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

EHC

2.22

Health Care Providers & Services Industry

Max
3.15
Q3
1.87
Median
0.74
Q1
0.27
Min
0.09

EHC’s P/S Ratio of 2.22 is in the upper echelon for the Health Care Providers & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

RGC

--

Pharmaceuticals Industry

Max
8.87
Q3
4.56
Median
2.14
Q1
1.58
Min
0.11

P/S Ratio data for RGC is currently unavailable.

EHC vs. RGC: A comparison of their Price-to-Sales Ratio (TTM) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

EHC

5.43

Health Care Providers & Services Industry

Max
7.33
Q3
4.45
Median
2.52
Q1
1.15
Min
0.66

EHC’s P/B Ratio of 5.43 is in the upper tier for the Health Care Providers & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

RGC

9.57

Pharmaceuticals Industry

Max
9.78
Q3
4.99
Median
2.48
Q1
1.53
Min
0.59

RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

EHC vs. RGC: A comparison of their Price-to-Book Ratio (MRQ) against their respective Health Care Providers & Services and Pharmaceuticals industry benchmarks.

Valuation at a Glance

SymbolEHCRGC
Price-to-Earnings Ratio (TTM)24.03--
Price-to-Sales Ratio (TTM)2.22--
Price-to-Book Ratio (MRQ)5.439.57
Price-to-Free Cash Flow Ratio (TTM)28.60--